INOZYME PHARMA, INC. Operating Income
INOZYME PHARMA, INC. reported Operating Income of -$27.69 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2025-05-14
- INOZYME PHARMA, INC. operating income (loss) for the quarter ending 2025-03-31 was -$27.69M.
- INOZYME PHARMA, INC. operating income (loss) for the quarter ending 2024-12-31 was -$27.17M.
- INOZYME PHARMA, INC. operating income (loss) for the quarter ending 2024-09-30 was -$24.85M.
- INOZYME PHARMA, INC. operating income (loss) for the quarter ending 2024-06-30 was -$27.66M.
- INOZYME PHARMA, INC. operating income (loss) for fiscal 2024 was -$104.03M.
- INOZYME PHARMA, INC. operating income (loss) for fiscal 2023 was -$75.64M.
- INOZYME PHARMA, INC. operating income (loss) for fiscal 2022 was -$68.67M.
- INOZYME PHARMA, INC. operating income (loss) for fiscal 2021 was -$56.65M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$27.69M 10-Q · filed 2025-05-14 | -$54.86M derived: sum of 2 quarters · filed 2025-05-14 | -$79.71M derived: sum of 3 quarters · filed 2025-05-14 | -$107.38M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | -$27.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$52.02M derived: sum of 2 quarters · filed 2025-03-10 | -$79.69M derived: sum of 3 quarters · filed 2025-03-10 | -$104.03M 10-K · filed 2025-03-10 |
| 2024-09-30 | -$24.85M 10-Q · filed 2024-11-05 | -$52.52M derived: sum of 2 quarters · filed 2024-11-05 | -$76.86M 10-Q · filed 2024-11-05 | -$99.67M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | -$27.66M 10-Q · filed 2024-08-06 | -$52.01M 10-Q · filed 2024-08-06 | -$74.82M derived: sum of 3 quarters · filed 2025-05-14 | -$92.89M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | -$24.34M 10-Q · filed 2025-05-14 | -$47.15M derived: sum of 2 quarters · filed 2025-05-14 | -$65.23M derived: sum of 3 quarters · filed 2025-05-14 | -$81.62M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$40.88M derived: sum of 2 quarters · filed 2025-03-10 | -$57.28M derived: sum of 3 quarters · filed 2025-03-10 | -$75.64M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$18.07M 10-Q · filed 2024-11-05 | -$34.47M derived: sum of 2 quarters · filed 2024-11-05 | -$52.84M 10-Q · filed 2024-11-05 | -$72.37M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$16.39M 10-Q · filed 2024-08-06 | -$34.76M 10-Q · filed 2024-08-06 | -$54.30M derived: sum of 3 quarters · filed 2024-08-06 | -$71.21M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$18.37M 10-Q · filed 2024-05-07 | -$37.90M derived: sum of 2 quarters · filed 2024-05-07 | -$54.81M derived: sum of 3 quarters · filed 2024-05-07 | -$70.20M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$19.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$36.45M derived: sum of 2 quarters · filed 2024-03-12 | -$51.84M derived: sum of 3 quarters · filed 2024-03-12 | -$68.67M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$16.91M 10-Q · filed 2023-11-07 | -$32.30M derived: sum of 2 quarters · filed 2023-11-07 | -$49.14M 10-Q · filed 2023-11-07 | -$67.90M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$15.39M 10-Q · filed 2023-08-08 | -$32.23M 10-Q · filed 2023-08-08 | -$50.99M derived: sum of 3 quarters · filed 2023-08-08 | -$65.25M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$16.84M 10-Q · filed 2023-05-09 | -$35.60M derived: sum of 2 quarters · filed 2023-05-09 | -$49.86M derived: sum of 3 quarters · filed 2023-05-09 | -$62.51M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$18.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$33.02M derived: sum of 2 quarters · filed 2023-03-22 | -$45.67M derived: sum of 3 quarters · filed 2023-03-22 | -$56.65M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$14.26M 10-Q · filed 2022-11-10 | -$26.92M derived: sum of 2 quarters · filed 2022-11-10 | -$37.89M 10-Q · filed 2022-11-10 | -$49.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$12.65M 10-Q · filed 2022-08-15 | -$23.63M 10-Q · filed 2022-08-15 | -$34.90M derived: sum of 3 quarters · filed 2022-08-15 | -$63.21M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$10.97M 10-Q · filed 2022-05-10 | -$22.24M derived: sum of 2 quarters · filed 2022-05-10 | -$50.56M derived: sum of 3 quarters · filed 2022-05-10 | -$60.11M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$39.59M derived: sum of 2 quarters · filed 2022-03-15 | -$49.13M derived: sum of 3 quarters · filed 2022-03-15 | -$57.04M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$28.32M 10-Q · filed 2021-11-09 | -$37.86M derived: sum of 2 quarters · filed 2021-11-09 | -$45.77M 10-Q · filed 2021-11-09 | -$52.54M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$9.55M 10-Q · filed 2021-08-11 | -$17.45M 10-Q · filed 2021-08-11 | -$24.22M derived: sum of 3 quarters · filed 2021-08-11 | -$28.54M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$7.91M 10-Q · filed 2021-05-12 | -$14.67M derived: sum of 2 quarters · filed 2021-05-12 | -$18.99M derived: sum of 3 quarters · filed 2021-05-12 | -$23.55M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$11.09M derived: sum of 2 quarters · filed 2021-03-25 | -$15.64M derived: sum of 3 quarters · filed 2021-03-25 | -$20.81M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$4.32M 10-Q · filed 2020-11-12 | -$8.87M derived: sum of 2 quarters · filed 2020-11-12 | -$14.04M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$4.55M 10-Q · filed 2020-09-03 | -$9.72M 10-Q · filed 2020-09-03 |